Home / Journals / CJU / Vol.25, No.2, 2018
Special Issues
  • Open AccessOpen Access

    EDITORIAL

    Prostate Cancer CRPC Stage M0 and M1: Do We Need Stage M0.5?

    Leonard G. Gomella
    Canadian Journal of Urology, Vol.25, No.2, pp. 9220-9220, 2018
    Abstract This article has no abstract. More >

  • Open AccessOpen Access

    LEGENDS IN UROLOGY

    LEGENDS IN UROLOGY

    Colonel David G. McLeod
    Canadian Journal of Urology, Vol.25, No.2, pp. 9221-9227, 2018
    Abstract This article has no abstract. More >

  • Open AccessOpen Access

    REVIEW

    Emerging, newly-approved treatments for lower urinary tract symptoms secondary to benign prostatic hypertrophy

    Hannah Pham, Pranav Sharma
    Canadian Journal of Urology, Vol.25, No.2, pp. 9228-9237, 2018
    Abstract Introduction: Oral therapy with alpha-blockers or 5-alpha reductase inhibitors remains the most common treatment for men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). For patients who progress or fail medical therapy, the standard of care continues to be transurethral resection of the prostate (TURP), a procedure with well-documented and durable outcomes. However, over the past decade, emerging minimally invasive options for LUS secondary to BPH have been developed, offering promising results with fewer side effects commonly associated with TURP, such as retrograde ejaculation and erectile dysfunction.
    Materials and methods: A literature review… More >

  • Open AccessOpen Access

    ARTICLE

    Stone culture in patients undergoing percutaneous nephrolithotomy: a practical point of view

    Amihay Nevo1,2, Roy Mano1,2, Ohad Shoshani1,2, Gherman Kriderman1,2, Eran Schreter1,2, David Lifshitz1,2
    Canadian Journal of Urology, Vol.25, No.2, pp. 9238-9244, 2018
    Abstract Introduction: This study aims to determine the clinical yield of stone culture in patients undergoing percutaneous nephrolithotomy (PCNL) and to identify those who may benefit from this test, particularly in predicting postoperative infections and guiding antimicrobial therapy. Materials and methods: We reviewed our institutional database for all patients who underwent PCNL between 2005 and 2017 and from whom both urine culture (UC) and stone culture (SC) results were available. The primary endpoint was the development of systemic inflammatory response syndrome (SIRS) within 48 hours post-procedure. Risk factors for SIRS and for stone colonization with highly resistant pathogens… More >

  • Open AccessOpen Access

    ARTICLE

    Supine percutaneous nephrolitotripsy in septuagenarian and octogenarian patients: outcomes of a case-control study

    Fábio C. M. Torricelli, Guilherme K. M. Ogawa, Fábio C. Vicentini, Giovanni S. Marchini, Alexandre Danilovic, Miguel Srougi, William C. Nahas, Eduardo Mazzucchi
    Canadian Journal of Urology, Vol.25, No.2, pp. 9245-9249, 2018
    Abstract Introduction: Currently, there is limited data evaluating the outcomes of supine percutaneous nephrolithotomy (PCNL) in septuagenarian and octogenarian patients. This study aims to compare the perioperative outcomes of supine PCNL in elderly patients (≥70 years) with those of a younger population (<70 years). Materials and methods: A matched case-control study was conducted from January 2009 through December 2015 using our prospectively maintained kidney stone database. The case group consisted of patients aged over 70 years, while the control group included patients under 70 years. Patients were randomly matched based on Guy’s Stone Score as a surrogate for… More >

  • Open AccessOpen Access

    ARTICLE

    Improving the utility of clinical phenotyping in interstitial cystitis/painful bladder syndrome: from UPOINT to INPUT

    Alice Crane, Jessica Lloyd, Daniel A. Shoskes
    Canadian Journal of Urology, Vol.25, No.2, pp. 9250-9254, 2018
    Abstract Introduction: The UPOINT phenotyping system has proven effective in classifying patients with urologic pelvic pain syndromes in a clinically meaningful way and guiding multimodal therapy. While highly successful in men with chronic prostatitis/chronic pelvic pain syndrome (CPPS), its utility is more limited in patients with interstitial cystitis/painful bladder syndrome (IC/PBS). This is because all IC/PBS patients, by definition, exhibit urinary and organ-specific symptoms. Furthermore, the AUA guidelines recommend a sequential tiered approach to treatment rather than the concurrent multimodal strategy used in UPOINT. Therefore, we aimed to modify the UPOINT system to make it more practical… More >

  • Open AccessOpen Access

    ARTICLE

    The comparative effectiveness of quadratus lumborum blocks and paravertebral blocks in radical cystectomy patients

    Austin J. Lee1, Jonathan G. Yabes2, Nathan Hale3, Ronald L. Hrebinko3, Jeffrey R. Gingrich3, Jodi K. Maranchie3, Mina M. Fam3, Robert M. Turner II3, Benjamin J. Davies3, Bruce Ben-David4, Bruce L. Jacobs3
    Canadian Journal of Urology, Vol.25, No.2, pp. 9255-9261, 2018
    Abstract Introduction: Multimodal analgesia is an effective strategy for managing postoperative pain and reducing opioid dependence. The quadratus lumborum block (QLB) and paravertebral block (PVB) are two regional anesthesia techniques that enhance multimodal pain management. In this study, we aimed to compare the efficacy of these two approaches in patients undergoing radical cystectomy. Materials and methods: A retrospective review was conducted on patients who underwent radical cystectomy between 2014 and 2016. Patients were divided into two groups based on the type of regional anesthesia received: bilateral continuous paravertebral blocks (n = 125) or bilateral single-shot quadratus lumborum blocks… More >

  • Open AccessOpen Access

    ARTICLE

    Open radical prostatectomy after transurethral resection: perioperative, functional, oncologic outcomes

    Charalampos Fragkoulis, Athanasios Pappas, Georgios Theocharis, Georgios Papadopoulos, Georgios Stathouros, Konstantinos Ntoumas
    Canadian Journal of Urology, Vol.25, No.2, pp. 9262-9267, 2018
    Abstract Introduction: This study aims to evaluate whether there are differences in perioperative, functional, and oncologic outcomes following radical retropubic prostatectomy (RRP) between patients who previously underwent transurethral resection of the prostate (TURP) and those who did not. Materials and methods: A total of 35 patients diagnosed with prostate cancer (clinical stages T1a or T1b) after TURP who subsequently underwent RRP and completed at least one year of follow-up were included in group A. These patients were matched 1:1 with a control cohort (group B, n = 35) based on age, body mass index (BMI), prostate-specific antigen (PSA)… More >

  • Open AccessOpen Access

    ARTICLE

    The transobturator suburethral sling: a safe and effective option for all degrees of post prostatectomy urinary incontinence

    John F. Sullivan, Paul N. Stassen, Diarmuid Moran, Eva M. Bolton, Lisa G. Smyth, Cliodhna M. Browne, James C. Forde, Raanan Tal, Thomas H. Lynch
    Canadian Journal of Urology, Vol.25, No.2, pp. 9268-9272, 2018
    Abstract Introduction: Male stress urinary incontinence (SUI) following radical prostatectomy (RP) is a common complication. While the artificial urinary sphincter (AUS) has traditionally been considered the surgical standard of care, the transobturator male sling has emerged as a viable alternative with distinct advantages, including lower complication rates and a less complex surgical technique. The aim of this study was to evaluate outcomes of a consecutive series of suburethral sling insertions using the AdVance sling in men with all degrees of post-RP SUI. Materials and methods: A prospective cohort of men who underwent AdVance sling placement for post-RP SUI… More >

  • Open AccessOpen Access

    ARTICLE

    Treatment of refractory category III nonbacterial chronic prostatitis/chronic pelvic pain syndrome with intraprostatic injection of onabotulinumtoxinA: a prospective controlled study

    Taha A. Abdel-Meguid1,2, Hisham A. Mosli1, Hasan Farsi1, Ahmad Alsayyad1, Abdulmalik Tayib1, Moataz Sait1, Ahmad Abdelsalam1,3
    Canadian Journal of Urology, Vol.25, No.2, pp. 9273-9280, 2018
    Abstract Introduction: To evaluate the efficacy and safety of intraprostatic injections of onabotulinumtoxinA (onaBoNT-A) to treat refractory chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).
    Materials and methods: Prospective two-group controlled study. Treatment group included adult men with refractory category-III nonbacterial CP/CPPS who underwent transurethral intraprostatic injections of onaBoNT-A (200 U). Control group included comparable patients who underwent cystoscopy only. Primary outcome was the proportion of 6-point responders (≥ 6 points reduction of total score of National Institutes of Health-Chronic Prostatitis Symptom Index [NIH-CPSI]) at 3 months. Secondary outcomes included proportions of quality of life (QoL) responders (≤ 2 points… More >

  • Open AccessOpen Access

    RESIDENT’S CORNER

    The disappearing PI-RADS 5 prostate lesion

    Vikram K. Sabarwal1,2, Cayde Ritchie3, Kareem Rayn4, Baris Turkbey5, Peter Pinto2
    Canadian Journal of Urology, Vol.25, No.2, pp. 9281-9283, 2018
    Abstract Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) identifies prostate cancer on the basis of multiparametric MRI (mpMRI). As an assessment tool, it correctly predicts clinically significant cancer in the vast majority of cases. In this light, we report a rare patient, for whom a PI-RADS 5 lesion vanished over the course of 13 months. More >

  • Open AccessOpen Access

    RESIDENT’S CORNER

    Secondary mucinous carcinoma of the prostate after low dose rate brachytherapy

    Sonja C. Murchison1, Mildred B. Martens3, Pauline Truong2, Abraham Alexander2
    Canadian Journal of Urology, Vol.25, No.2, pp. 9284-9287, 2018
    Abstract Radiation induced malignancy (RIM) after treatment for prostate cancer is well documented after external beam irradiation, but less so in the setting of brachytherapy. We report a case of mucinous adenocarcinoma of the prostate, consistent with a RIM, which developed 12 years after low dose rate brachytherapy for low risk prostate adenocarcinoma. Diagnostic and therapeutic considerations of RIM are discussed. As long term survivors are followed in the community by primary care physicians and urologists, awareness of RIM as a potential late effect of brachytherapy is important to ensure that cases are diagnosed and managed More >

  • Open AccessOpen Access

    HOW I DO IT

    How I Do It: Hydrogel spacer placement in men scheduled to undergo prostate radiotherapy

    Juan Montoya, Eric Gross, Lawrence Karsh
    Canadian Journal of Urology, Vol.25, No.2, pp. 9288-9293, 2018
    Abstract Hydrogel spacer placement between the prostate and rectum in men scheduled to undergo prostate radiotherapy is an emerging technique well suited for urologists. The hydrogel spacer reduces rectal injury during radiotherapy by displacing the rectum away from the high dose region. Following radiotherapy the hydrogel spacer then liquifies, is absorbed, and then clears via renal filtration in approximately 6 months. Herein we describe the appropriate patients eligible for this procedure, and the application technique we use in our clinic. More >

Per Page:

Share Link